RxDoctor Payments Data

Eric Pfeifer, OD

Optometrist · Saint Louis, MONPI 1205567138

Payments from drug & device makers

$1,561in general payments, 2019–2025

Across 66 payments — averaging $23.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$214
  • AbbVie$213
  • Tarsus Pharmaceuticals, Inc.$202
  • Sun Pharmaceutical Industries Inc.$163
  • Oyster Point Pharma, Inc.$154
  • Bausch & Lomb Americas Inc.$119
  • plus $497 from 10 others

What the payments were for

  • Speaking & faculty fees$282%
  • Food & beverage$1,53398%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,561 in reported general payments places this provider in the 65th percentile of 1,030 optometrist providers in Missouri.

See all optometrist providers in Missouri

Medicare billing

Part B allowed, 2024
$113,021
Medicare patients
587
Services billed
1,383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclosporine27$19,695
LumiganBimatoprost17$8,232
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$3,878
Fluorometholone33$2,623
Latanoprost223$2,560
Travoprost19$2,549
ValacyclovirValacyclovir Hcl12$1,986
Prednisolone Acetate48$1,532
Tobramycin-DexamethasoneTobramycin/Dexamethasone26$1,285
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat74$890
Brimonidine Tartrate21$539
Timolol Maleate44$455
Doxycycline Hyclate26$282
Dorzolamide Hcl14$261
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha11$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$213$8,23217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,030 optometrist providers in Missouri.

Other optometrist in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →